Aims & Scope
Cancer Control is a JCR-ranked open access journal whose mission is to advance the prevention, detection, diagnosis, treatment, and palliative care of cancer by enabling researchers, doctors, policymakers, and other healthcare professionals to freely share research along the cancer control continuum.
Our vision is a world where gold-standard cancer care is the norm, not the exception.
The journal is organized into five topical sections, as well as a sixth curated by members of the Moffitt Cancer Center.
The topical sections are inspired by the foci of the cancer control continuum (prevention, detection, diagnosis, treatment, survivorship).
Article Types and Topics of Interest Cancer Control welcomes original research (both basic and clinical studies), reviews, and commentaries.
We encourage submissions relating to advances in the following areas: Communications in cancer research Surveillance Social Determinants of Health Disparities Genetic Testing Decision-Making Dissemination of Evidence-Based Interventions Health Care Delivery and Quality of Care Epidemiology Measurement.
View Aims & ScopeMetrics & Ranking
Impact Factor
Year | Value |
---|---|
2025 | 2.6 |
2024 | 2.50 |
Journal Rank
Year | Value |
---|---|
2024 | 5877 |
Journal Citation Indicator
Year | Value |
---|---|
2024 | 1271 |
SJR (SCImago Journal Rank)
Year | Value |
---|---|
2024 | 0.881 |
Quartile
Year | Value |
---|---|
2024 | Q2 |
h-index
Year | Value |
---|---|
2024 | 83 |
Impact Factor Trend
Abstracting & Indexing
Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.
Subjects & Keywords
Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.
Licensing & Copyright
This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.
Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.
Policy Links
This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.
- Aims scope
- Homepage
- Oa statement
- Author instructions
- License terms
- Review url
- Board url
- Copyright url
- Plagiarism url
- Preservation url
- Apc url
- License
Plagiarism Policy
This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.
For more details, please refer to our official: Plagiarism Policy.
APC Details
The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine, ensuring accessibility and quality in research dissemination.
This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 2,650.00 USD. Learn more.
Explore journals without APCs for alternative publishing options.
Most Cited Articles
The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.
-
Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein
Citation: 722
Authors: Hilary, Helen M.
-
Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Citation: 454
Authors: Nader N., Hashem B.
-
Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients with Cancer
Citation: 384
Authors: Lauren M., Louis A., Terrance L., Elisabeth, Clement K., Susan
-
Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers
Citation: 246
Authors: Paul G., Teru, Kenneth C.
-
Liver Resection and Surgical Strategies for Management of Primary Liver Cancer
Citation: 238
Authors: Sonia T., Daniel A.
-
The Molecular Biology of Endometrial Cancers and the Implications for Pathogenesis, Classification, and Targeted Therapies
Citation: 230
Authors: Nisha, Vimala, Robert M.
-
Endometrial Cancer and Lynch Syndrome: Clinical and Pathologic Considerations
Citation: 218
Authors: Larissa A., Russell R., Karen H.
-
Teachable Moments for Promoting Smoking Cessation: The Context of Cancer Care and Survivorship
Citation: 197
Authors: Colleen M., Jamie S.